EntreMed Presents Phase 2 Results for Panzem(R) NCD Brain Cancer Study Presented at ASCO.

0 Comments | M2 Presswire, June, 2007

M2 PRESSWIRE-5 June 2007-Headline Maker: EntreMed Presents Phase 2 Results for Panzem(R) NCD Brain Cancer Study Presented at ASCO(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:05062007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets.

Activity on the NASDAQ market has brought this company to the attention of our research team. EntreMed, Inc. (Nasdaq: ENMD), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. June 5 - EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)